Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis

Yi-Chun Kuan 1,2,3,4,5,†, Kuang-Wei Huang 6,†, Cheng-Li Lin 7,8, Jiing-Chyuan Luo 9 and Chia-Hung Kao 10,11,12,*

1 Department of Neurology, Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan
2 Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei 10617, Taiwan
3 Center for Evidence-Based Health Care, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan
4 Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
5 Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
6 Division of Gastroenterology, Department of Internal Medicine, Taipei Beitou Health Management Hospital, Taipei 11252, Taiwan
7 Management Office for Health Data, China Medical University Hospital, Taichung 40402, Taiwan
8 College of Medicine, China Medical University, Taichung 40402, Taiwan
9 Division of Gastroenterology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan
10 Graduate Institute of Biomedical Sciences and School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan
11 Department of Nuclear Medicine and PET Center, and Center of Augmented Intelligence in Healthcare, China Medical University Hospital, Taichung 40402, Taiwan
12 Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan
* Correspondence: d10040@mail.cmuh.org.tw or dr.kaochiahung@gmail.com
† Yi-Chun Kuan and Kuang-Wei Huang contributed equally to this article.

Received: 26 June 2019; Accepted: 23 July 2019; Published: 25 July 2019

Abstract: Objective: A window period of approximately 3–6 months is usually adopted in studies that evaluate hepatic encephalopathy (HE) risk in proton pump inhibitor (PPI) users. However, HE risk after short-term PPI exposure remains unclear. We explored the effect of short-term PPI exposure using a case-crossover study design. Design: Records of patients with decompensated cirrhosis who had received an HE diagnosis were retrieved from the National Health Insurance Research Database. PPI use rates were compared for case and control with window periods of 7, 14, and 28 days. The adjusted self-matched odds ratio (OR) and 95% confidence interval (CI) from a conditional logistic regression model were used to determine the association between PPI use and HE risk. Results: Overall, 13,195 patients were analyzed. The adjusted OR for HE risk after PPI exposure was 3.13 (95% CI = 2.33–4.20) for the 7-day window, 4.77 (95% CI = 3.81–5.98) for the 14-day window, and 5.60 (95% CI = 4.63–6.78) for the 28-day window. All PPI categories, except omeprazole and pantoprazole, were associated with an increased HE risk. Irrespective of other precipitating factors, such as recent gastrointestinal bleeding or infection, PPI significantly increased HE risk. Conclusion: Short-term PPI use is significantly associated with HE in patients with decompensated cirrhosis. Physicians should use PPI in these patients for appropriate indications, and carefully monitor signs of HE even after short-term exposure. Owing to the limitations of retrospective design in the current study, further study is warranted to confirm our findings.
Keywords: proton pump inhibitor; hepatic encephalopathy; Short-term Registry for Catastrophic Illness Patient Database

1. Introduction

Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of liver cirrhosis. The clinical spectrum ranges from minimal HE to overt HE, which may result in altered consciousness or even coma [1]. HE development is associated with short survival in patients with cirrhosis [2,3]. Additional factors are involved in triggering HE, and identifying these factors early is essential to treat HE effectively. These predisposing factors include electrolyte imbalance, high protein intake, gastrointestinal (GI) bleeding, infection, constipation, and medication such as benzodiazepines or narcotics [4–8].

Proton pump inhibitors (PPIs) are the most widely used medication worldwide for managing acid-related disorders, including gastroesophageal reflux disease and peptic ulcer disease. However, PPI may predispose patients to small bowel bacterial overgrowth (SIBO) and bacterial translocation [9]. SIBO is common in liver cirrhosis, which can be correlated with its severity and linked with minimal and overt HE [10].

Several recent studies have raised concerns, but they have shown conflicting results regarding the possible association between PPI and HE in patients with cirrhosis [11–16]. PPI exposure with approximately 3- to 6-month window [12,17] or vaguely defined window [11,13–15] has been often used to evaluate HE risk in chronic PPI users. To date, HE risk in patients with decompensated cirrhosis after short-term PPI exposure remains uncertain. Furthermore, the existence of residual confounding factors from observational epidemiology with odds ratios (ORs) <3 should be considered before any suggestion of causality is entertained [18]. To overcome the potential confounding variables not generally available in population studies and to evaluate the effect of short-term PPI exposure, we conducted a case-crossover study in patients with decompensated cirrhosis diagnosed with HE from Taiwan’s nationwide population-based claims database.

2. Methods

2.1. Case-Crossover Design

The case-crossover design, first introduced by Maclure in 1991, is a research method for studying transient effects on acute event risk [19]. The case-crossover study design was devised to assess the relationship between transient exposures and acute outcomes in situations where the control series of a case-control study is difficult to achieve. Each individual patient serves as their own control in the case-crossover design (Figure 1). Therefore, stable confounders that are unknown, poorly measured, or cannot be measured eliminate each other.

*Index date = date of hepatic encephalopathy.

Figure 1. Illustration of case-crossover design to evaluate hepatic encephalopathy risk after short-term proton pump inhibitor (PPI) exposure.
2.2. Data Source and Study Population

Launched in 1995, the National Health Insurance (NHI) program in Taiwan provides comprehensive medical care and covers >99% of the Taiwanese population (23.75 million people). The Taiwan National Health Insurance Research Database (NHIRD) is a large medical claims database and contains the data of beneficiaries enrolled in the Taiwan NHI program. It contains information regarding disease diagnosis coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) as well as treatment procedures, service dates, and medical costs of beneficiaries and the names of nearly 20,000 prescription drugs that they have used. All data are anonymous and de-identified using encrypted and unique personal identification numbers to make the NHI reimbursement data suitable for public research.

From the NHIRD, we selected patients who had advanced decompensated cirrhosis (ICD-9-CM 571.2, 571.5, and 571.6). Decompensated cirrhosis was defined as the development of: (1) cirrhosis with refractory ascites; (2) cirrhosis with hepatorenal syndrome; or (3) cirrhosis with esophageal or gastric varices with bleeding. The diagnoses were confirmed according to patients’ inclusion in the NHIRD. Adult patients (≥18 years old) with newly diagnosed HE (ICD-9-CM 572.2) were included for analysis. Cirrhosis etiology, hepatic decompensation at enrollment, and medical comorbidities in the past 3 months, such as GI bleeding, intra-abdominal infection, pneumonia, and urinary tract infection, defined according to ICD-9-CM codes, were included for analysis. The Charlson comorbidity index was used to assess comorbidity severity.

2.3. Ethics Statement

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH-104-REC2-115-CR3). The IRB also specifically waived the consent requirement.

2.4. Data Processing and Statistical Analysis

Descriptive data are expressed as mean ± standard deviation (SD) for continuous variables and as numbers of cases and percentages for categorical variables. The OR of the 7-day window for HE risk after exposure to a specific drug was estimated by the ratio of patients who were exposed to that drug during the 7-day case period (1–7 days before the index date) to patients who were exposed only during the 7-day control period (8–14 days before the index date). For case-crossover analyses, conditional logistic regression models were used to estimate the OR and their 95% confidence intervals (95% CIs). In the multivariate analysis, an adjusted OR was estimated after controlling for cirrhosis etiology, hepatic decompensation at enrollment, Charlson Comorbidity Index score, and medical comorbidities in the past 3 months. We performed a sub-analysis to investigate the association between the individual PPI use and HE risk after stratifying by each PPI category (pantoprazole, lansoprazole, omeprazole, esomeprazole, and rabeprazole). Subgroup analyses were performed by stratifying characteristics such as gender, age (≤49, 50–64, and ≥65 years), and medical comorbidities in the past 3 months. All data analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). A two-tailed \( p \) value of <0.05 was considered statistically significant.

3. Results

Overall, data of 13,195 patients aged ≥18 years with new-onset HE episode were retrieved from the NHIRD. The mean age at HE onset was 56.6 years (SD = 13.2), and 70.3% of the study participants were male. Furthermore, most of the participants had hepatic decompensation at enrollment, with 70.4% patients having varices or a history of varices bleeding followed by 60.0% and 0.6% patients having...
ascites and hepatorenal syndrome, respectively. The baseline demographic and clinical characteristics of the included patients are summarized in Table 1.

Table 2 presents the effect of PPI use on HE risk with different window periods. Overall, PPI use was associated with increased HE risk in patients with decompensated cirrhosis after adjusting for potential confounding factors. During the 7-, 14-, and 28-day window periods, PPI users had a 3.13- to 4.77-fold (95% CI = 2.33–4.20, 4.77–5.98, and 5.60-fold (95% CI = 4.63–6.78) increased HE risk, respectively. Stratified by each individual PPI, the use of lansoprazole (OR = 4.38; 95% CI = 2.76–6.97), esomeprazole (OR = 5.14; 95% CI = 2.30–11.5), and rabeprazole (OR = 3.62; 95% CI = 1.02–12.9), but not omeprazole (OR = 1.85; 95% CI = 0.86–3.98) and pantoprazole (OR = 1.36; 95% CI = 0.72–2.58), was associated with an increased HE risk (Table 3). In the subgroup analyses, HE risk did not differ with age (age ≤ 49, OR = 1.61, 95% CI = 1.26–2.05; 50 ≤ age ≤ 64, OR = 2.00, 95% CI = 1.59–2.52; age ≥ 65, OR = 2.37, 95% CI = 1.82–3.09) or gender (female, OR = 2.05, 95% CI = 1.57–2.68; male, OR = 1.91, 95% CI = 1.62–2.25). We also tested the effect of PPI use on patients with or without precipitating factors for HE, such as recent GI bleeding and infection. Overall, PPI use significantly increased HE risk in patients with and without precipitating factors, with a higher risk trend in patients with precipitating factors as compared with those without (Table 4).

Table 1. Demographic data of patients with decompensated cirrhosis and hepatic encephalopathy. HBV: hepatitis B virus; HCV: hepatitis C virus.

| Characteristic                          | Cases (N = 13,195) |
|----------------------------------------|-------------------|
|                                        | Mean  | SD   |
| Age (years)                            | 56.6  | 13.2 |
| Gender                                 |       |      |
| Male                                   | 9271  | 70.3 |
| Female                                 | 3924  | 29.7 |
| Cirrhosis etiology                     |       |      |
| HBV-related                            | 4702  | 35.6 |
| HCV-related                            | 3982  | 30.2 |
| Alcohol-related                        | 7351  | 55.7 |
| Hepatic decompensation at enrollment   |       |      |
| Ascites                                | 7920  | 60.0 |
| Varices or varices bleeding            | 9284  | 70.4 |
| Hepatorenal syndrome                   | 79    | 0.60 |
| Charlson Comorbidity Index score       |       |      |
| 0                                      | 315   | 2.39 |
| 1                                      | 3680  | 27.9 |
| 2                                      | 5709  | 43.3 |
| 3+                                     | 3491  | 26.5 |
| Medical comorbidities in recent 3 months|      |      |
| GI bleeding                            | 3151  | 23.9 |
| Intra-abdominal infection              | 955   | 7.24 |
| Pneumonia                              | 271   | 2.05 |
| Urinary tract infection                | 275   | 2.08 |
Table 2. Hepatic encephalopathy risk associated with current proton pump inhibitor use.

|                      | Case N = 13,195 | Control N = 13,195 | Crude OR 95% CI | Adjusted * OR 95% CI |
|----------------------|-----------------|--------------------|-----------------|----------------------|
| 7 day window Proton  | 1779            | 977                | 2.18 1.99–2.39  | 3.13 2.33–4.20       |
| pump inhibitor       |                 |                    |                 |                      |
| 14 day window        | 2459            | 1192               | 2.82 2.59–3.08  | 4.77 3.81–5.98       |
| Proton pump inhibitor|                 |                    |                 |                      |
| 28 day window        | 3155            | 1268               | 3.86 3.55–4.21  | 5.60 4.63–6.78       |
| Proton pump inhibitor|                 |                    |                 |                      |

* Adjusted for cirrhosis etiology, hepatic decompensation at enrollment, Charlson Comorbidity Index score, and medical comorbidities in recent 3 months.

Table 3. Hepatic encephalopathy risk associated with different proton pump inhibitors for a 14-day window period.

|                      | Case N = 13,195 | Control N = 13,195 | Crude OR 95% CI | Adjusted * OR 95% CI |
|----------------------|-----------------|--------------------|-----------------|----------------------|
| Pantoprazole         | 299             | 178                | 1.92 1.55–2.37  | 1.36 0.72–2.58       |
| Lansoprazole         | 722             | 397                | 2.16 1.87–2.48  | 4.38 2.76–6.97       |
| Omeprazole           | 255             | 140                | 2.29 1.79–2.94  | 1.85 0.86–3.98       |
| Esomeprazole         | 374             | 195                | 2.30 1.88–2.81  | 5.14 2.30–11.5       |
| Rabeprazole          | 129             | 67                 | 2.55 1.77–3.68  | 3.62 1.02–12.9       |

* Adjusted for cirrhosis etiology, hepatic decompensation at enrollment, Charlson Comorbidity Index score, and medical comorbidities in recent 3 months.

Table 4. Hepatic encephalopathy risk associated with proton pump inhibitor for a 28-day window period stratified by current medical comorbidities.

|                      | Case N = 13,195 | Control N = 13,195 | Crude OR 95% CI | Adjusted * OR 95% CI |
|----------------------|-----------------|--------------------|-----------------|----------------------|
| GI bleeding          |                 |                    |                 |                      |
| Yes                  | 605             | 247                | 2.91 2.35–3.61  | 2.71 2.10–3.49       |
| No                   | 2550            | 1021               | 2.97 2.75–3.21  | 1.42 1.29–1.56       |
| Intra-abdominal      |                 |                    |                 |                      |
| infection            |                 |                    |                 |                      |
| Yes                  | 183             | 60                 | 3.86 2.52–5.90  | 3.93 2.32–6.65       |
| No                   | 2972            | 1208               | 2.92 2.72–3.34  | 1.43 1.31–1.57       |
| Pneumonia            |                 |                    |                 |                      |
| Yes                  | 50              | 20                 | 1.96 0.96–3.99  | 1.63 0.69–3.85       |
| No                   | 3105            | 1248               | 2.96 2.76–3.17  | 1.46 1.34–1.59       |
| Urinary tract infection |              |                    |                 |                      |
| Yes                  | 26              | 8                  | 4.62 1.72–12.4  | 10.8 2.58–45.6       |
| No                   | 3129            | 1260               | 2.95 2.75–3.17  | 1.45 1.33–1.58       |

* Mutually adjusted for cirrhosis etiology, hepatic decompensation at enrollment, and Charlson Comorbidity Index score.

4. Discussion

In the current population-based case-crossover study, we observed that short-term PPI exposure is associated with a significant HE risk in patients with decompensated cirrhosis in different window periods (7–28 days).

First reported in 2014, Lin et al. found that HE occurrence is associated with hyponatremia (OR = 6.318, 95% CI = 2.803–14.241) and PPI use (OR = 4.392, 95% CI = 1.604–12.031) in patients with acute-on-chronic liver failure [15]. In recent years, 2 large studies from Denmark [11] and Taiwan [12]
have again raised concerns about the possible association between PPI and HE in patients with cirrhosis. However, some limitations exist, such as small patient numbers from Lin et al., potential existence of residual confounding factors due to OR < 3 from Tsai et al. [12], and increased risk of bias due to enrollment of only those patients who had ascites and were treated with satavaptan or other diuretic drugs from Dam et al. [11]. Furthermore, PPI exposure has been defined vaguely in different studies. Moreover, only Tsai et al. found a dose-dependent HE risk among PPI users with cirrhosis. In previous studies, some confounders including lifestyle differences such as alcohol drinking, underlying comorbidities, and disease severity were not fully considered or were unavailable in research databases. Lifestyle factors such as alcoholism were strongly related to HE development in patients with decompensated cirrhosis or acute-on-chronic liver failure [20]. Uneven distribution of reported comorbidities between case and control groups may adversely affect the final results [12,15].

To overcome these potential biases, we conducted a case-crossover study [19] to look at the possible influence of short periods of prior PPI use over 3 different intervals up to 28 days. With this measurement, stable confounders that are unknown, poorly measured, or cannot be measured would be eliminated. However, considering the large sample size recruited from the NHIRD, sufficient power for statistical analyses would be obtained.

We observed that PPI exposure was associated with an elevated HE risk in all 3 window periods. The risk was the highest for the 28-day window (OR = 5.60) followed by the 14-day window (OR = 4.77) and 7-day window (OR = 3.13). The trend of increasing the window period may support the finding of dose-response relationship found by Tsai et al. Some studies have indicated that age is an additional risk factor for HE [11,21]. Subgroup analyses of the current case-crossover study indicated that PPI use independently increased HE risk in different age groups with increasing trend. In current study, we found esomeprazole, rabeprazole and lansoprazole were associated with risk of HE, but not omeprazole and pantoprazole. Esomeprazole and rabeprazole were more potent on the effect of gastric acid suppression [22]. Gastric acid suppression may play a role of SIBO, which contribute to further HE. No significant association of pantoprazole and omeprazole with HE may be due to their relatively low potency for gastric acid suppression [22], and pharmacokinetic studies have shown that lansoprazole may penetrate the blood-brain barrier [23]. Furthermore, HE could be triggered by the accumulation of drugs or toxic metabolites through PPI by modulating blood–brain barrier drug transport [24]. Therefore, these may explain why some PPIs are implicated in the induction of HE in current study. GI bleeding and infection were considered crucial precipitating factors for HE, and they may affect the statistical results [6–8]. These factors were not measured [11] or have been unevenly distributed [12,15] in previous cohort or case-control studies. Studies have shown conflicting results regarding the association between PPI and HE after adjustment of these precipitating factors [13]. Therefore, we performed subgroup analyses through stratification of patients with or without these precipitating factors for clarifying the effect of PPI exposure. Overall, PPI use still significantly increased HE risk in patients with decompensated cirrhosis without recent GI bleeding (adjusted OR = 1.42; 95% CI = 1.29–1.56) or infection such as intra-abdominal infection (adjusted OR = 1.43; 95% CI = 1.31–1.57), pneumonia (adjusted OR = 1.46; 95% CI = 1.34–1.59), or urinary tract infection (adjusted OR = 1.45; 95% CI = 1.33–1.58). These findings, along with a recently published study from Tsai et al. [12], may be interpreted as the risk of HE in such conditions is attributed to PPI per se rather than precipitating factors. Moreover, the greater risk of HE in PPI users concomitant with precipitating factors as compared to those without may support the additive influence each other.

The mechanism underlying the association between the PPI and HE risk may be complex. In patients with cirrhosis, pathological bacterial translocation involving impaired intestinal motility, SIBO, intestinal barrier dysfunction, systemic inflammation, and altered gut flora and their by-products, such as ammonia and endotoxins, may play a key role in HE pathogenesis [10]. First, PPI may increase SIBO incidence [9], which is associated with minimal HE occurrence [25,26]. Second, PPI delays gastric motility and emptying [27], which can lead to SIBO caused by stasis of food and bacteria in the upper GI tract. Third, PPI therapy inhibits neutrophil-endothelial cell interactions [28] and impaired mucosal
antimicrobial host defense mechanisms, which contribute to bacterial translocation development in cirrhosis [29]. Fourth, PPI has been linked with altered gut microbiota [30,31], which is associated with cirrhosis and its complications [32]. Finally, apart from microbiota-dependent mechanisms, PPI may cause drugs or toxic metabolites to accumulate in the brain through P-glycoprotein drug-drug interaction at the blood-brain barrier [24].

Owing to several advantages of the current study, the results have increased validity. First, a relatively large number of patients and population-based design, which involved data from the NHIRD, provided generalizable findings. Second, to increase the diagnostic accuracy for liver cirrhosis, we included patients with advanced decompensated cirrhosis who met the diagnoses definition (mentioned in the Methods section) confirmed according to the patients’ inclusion in the NHIRD. Third, the case-crossover design eliminates within-individual time-invariant variables. However, the current study has several limitations. First, this was a retrospective design study, and the study population was selected from a claims-based data set. Some selection biases may exist; therefore, the results must be extrapolated with caution. Second, we identified patients with HE on the basis of ICD-9-CM code. Overt HE probably accounts for the majority HE, and minimal HE may be missed as it lacks obvious clinical signs and is usually determined through psychometric and neurophysiological tests [4,33]. Third, the exact indications for PPI prescriptions were unknown in the current study. Furthermore, these conditions may contribute to HE development independently of PPI usage. For example, GI bleeding or stress ulcers caused by infection would potentially lead to HE. However, we performed subgroup analyses by stratifying patients with or without these precipitating conditions for clarifying the effect of PPI exposure. Fourth, though the case-crossover design could automatically control for all time-invariant confounders, it is likely that our results were still confounded by time-variant factors, such as hyponatremia and excessive protein intake, which are not available in the NHIRD.

In conclusion, short-term (7–28 days) exposure to PPI is associated with a significantly increased HE risk in patients with decompensated cirrhosis, regardless of age, gender, and recent precipitating comorbidities. Physicians should use PPI in these patients for appropriate indications and carefully monitor HE signs even after short-term exposure. Due to the limitations of retrospective design in our study, further studies, such as prospective or randomized controlled trials, may be warranted to confirm our findings.

Author Contributions: All authors have contributed significantly, and that all authors are in agreement with the content of the manuscript: Conception and design: Y.-C.K., K.-W.H., C.-H.K. Administrative support: C.-H.K. Collection and assembly of data: All authors. Data analysis and interpretation: All authors. Manuscript writing: All authors. Final approval of manuscript: All authors.

Funding: This work was supported by grants from the Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW108-TDU-B-212-133004); China Medical University Hospital (CMU106-ASIA-12, DMR-107-192); Academia Sinica Stroke Biosignature Project (BM1070101021); MOST Clinical Trial Consortium for Stroke (MOST 107-2321-B-039-004-); Tseng-Lien Lin Foundation, Taichung, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Conflicts of Interest: The authors declare no conflict of interest related to this study.

References
1. Flamm, S.L. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy. Am. J. Med. Sci. 2018, 356, 296–303. [CrossRef] [PubMed]
2. Bustamante, J.; Rimola, A.; Ventura, P.J. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J. Hepatol. 1999, 30, 890–895. [CrossRef]
3. Stewart, C.A.; Malinchoc, M.; Kim, W.R. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl. 2007, 13, 1366–1371. [CrossRef] [PubMed]
4. Vilstrup, H.; Amodio, P.; Bajaj, J. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014, 60, 715–735. [CrossRef] [PubMed]
5. Pantham, G.; Post, A.; Venkat, D.; Einstadter, D.; Mullen, K.D. A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis. *Dig. Dis. Sci.* **2017**, *62*, 2166–2173. [CrossRef] [PubMed]

6. Strauss, E.; Costa, M.F. The importance of bacterial infections as precipitating factors of chronic hepatic encephalopathy in cirrhosis. *Hepato Gastroenterol.* **1998**, *45*, 900–904.

7. Mumtaz, K.; Ahmed, U.S.; Abid, S. Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis. *J. Coll. Physicians Surg. Pak.* **2010**, *20*, 514–518.

8. Maqsood, S.; Saleem, A.; Iqbal, A.; Butt, J.A. Precipitating factors of hepatic encephalopathy: Experience at Pakistan Institute of Medical Sciences Islamabad. *J. Ayub Med. Coll. Abbottabad* **2006**, *18*, 58–62.

9. Lo, W.K.; Chan, W.W. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: A meta-analysis. *Clin. Gastroenterol. Hepatol.* **2013**, *11*, 483–490. [CrossRef]

10. Rai, R.; Saraswat, V.A.; Dhiman, R.K. Gut microbiota: Its role in hepatic encephalopathy. *J. Clin. Exp. Hepatol.* **2015**, *5*, S29–S36. [CrossRef]

11. Dam, G.; Vilstrup, H.; Watson, H. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. *Hepatology* **2016**, *64*, 1265–1272. [CrossRef] [PubMed]

12. Tsai, C.F.; Chen, M.H.; Wang, Y.P. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients with Cirrhosis in a Population Study. *Gastroenterology* **2017**, *152*, 134–141. [CrossRef] [PubMed]

13. Sakamaki, A.; Yokoo, T.; Kamimura, K.; Farcomeni, A.; Merli, M.; Riggio, O. Proton pump inhibitors do not increase the incidence of hepatic encephalopathy: A multicenter retrospective study in niigata prefecture. *Hepatology* **2018**, *68*, 1173A.

14. Zhu, J.; Qi, X.; Yu, H.; Li, J.; Han, D.; Guo, X. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis. *United Eur. Gastroenterol. J.* **2018**, *6*, 1179–1187. [CrossRef]

15. Lin, Z.N.; Zuo, Y.Q.; Hu, P. Association of Proton Pump Inhibitor Therapy with Hepatic Encephalopathy in Hepatitis B Virus-related Acute-on-Chronic Liver Failure. *Hepat. Mon.* **2014**, *14*, e16258. [CrossRef]

16. Tapper, E.B.; Henderson, J.; Baki, J. Incidence and predictors of hepatic encephalopathy in a population-based cohort of older americans with cirrhosis: Role of opiates, benzodiazepines and proton-pump inhibitors (PPIs). *Hepatology* **2018**, *68*, 138A.

17. Khan, M.A.; Cholankeril, G.; Howden, C.W. Proton Pump Inhibitors and the Possible Development of Hepatic Encephalopathy in Cirrhotic Patients: True Association or Residual Confounding? *Gastroenterology* **2017**, *152*, 2076. [CrossRef]

18. Maclure, M. The case-crossover design: A method for studying transient effects on the risk of acute events. *Am. J. Epidemiol.* **1991**, *133*, 144–153. [CrossRef]

19. Mehta, G.; Mookerjee, R.P.; Sharma, V.; Jalan, R. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure. *Liver Int.* **2015**, *35*, 724–734. [CrossRef]

20. Dasani, B.M.; Sigal, S.H.; Lieber, C.S. Analysis of risk factors for chronic hepatic encephalopathy: The role of Helicobacter pylori infection. *Am. J. Gastroenterol.* **1998**, *93*, 726–731. [CrossRef] [PubMed]

21. Kirchheiner, J.; Glatt, S.; Fuhr, U.; Klotz, U.; Meineke, I.; Seufferlein, T.; Brockmoller, J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. *Eur. J. Clin. Pharmacol.* **2009**, *65*, 19–31. [CrossRef] [PubMed]

22. Rojo, L.E.; Alzate-Morales, J.; Saavedra, I.N.; Davies, P.; Maccioni, R.B. Selective interaction of lansoprazole and astemizole with tau polymers: Potential new clinical use in diagnosis of Alzheimer’s disease. *J. Alzheimers Dis.* **2010**, *19*, 573–589. [CrossRef] [PubMed]

23. Assaraf, J.; Weiss, N.; Thabut, D. Proton Pump Inhibitor Administration Triggers Encephalopathy in Cirrhotic Patients by Modulating Blood-Brain Barrier Drug Transport. *Gastroenterology* **2017**, *152*, 2077. [CrossRef] [PubMed]

24. Gupta, A.; Dhiman, R.K.; Kumari, S.; Rana, S.; Agarwal, R.; Duseja, A.; Chawla, Y. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. *J. Hepatol.* **2010**, *53*, 849–855. [CrossRef]
26. Lunia, M.K.; Sharma, B.C.; Sachdeva, S. Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy. *Hepatol. Int.* 2013, 7, 268–273. [CrossRef] [PubMed]

27. Sanaka, M.; Yamamoto, T.; Kuyama, Y. Effects of proton pump inhibitors on gastric emptying: A systematic review. *Dig. Dis. Sci.* 2010, 55, 2431–2440. [CrossRef]

28. Yoshida, N.; Yoshikawa, T.; Tanaka, Y.; Fujita, N.; Kassai, K.; Naito, Y.; Kondo, M. A new mechanism for anti-inflammatory actions of proton pump inhibitors—Inhibitory effects on neutrophil-endothelial cell interactions. *Aliment. Pharmacol. Ther.* 2000, 14, 74–81. [CrossRef]

29. Töltsczik, Z.; Wiest, R.; Beisner, J.; Nuding, S.; Hofmann, C.; Schoelmerich, J.; Bevins, C.L.; Stange, E.F.; Wehkamp, J. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. *Hepatology* 2012, 55, 1154–1163. [CrossRef]

30. Jackson, M.A.; Goodrich, J.K.; Maxan, M.E.; Ley, R.E.; Bell, J.T.; Spector, T.D.; Steves, C.J. Proton pump inhibitors alter the composition of the gut microbiota. *Gut* 2016, 65, 749–756. [CrossRef]

31. Freedberg, D.E.; Toussaint, N.C.; Chen, S.P.; Ratner, A.J.; Whittier, S.; Wang, T.C.; Wang, H.H.; Abrams, J.A. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. *Gastroenterology* 2015, 149, 883–885. [CrossRef] [PubMed]

32. Bajaj, J.S.; Heuman, D.M.; Hylemon, P.B. Altered profile of human gut microbiome is associated with cirrhosis and its complications. *J. Hepatol.* 2014, 60, 940–947. [CrossRef] [PubMed]

33. Shawcross, D.L.; Dunk, A.A.; Jalan, R.; Kircheis, G.; Knecht, R.J.; Laleman, W.; Ramage, J.K.; Wedemeyer, H.; Morgan, I.E. How to diagnose and manage hepatic encephalopathy: A consensus statement on roles and responsibilities beyond the liver specialist. *Neurogastroenterol. Motil.* 2016, 28, 146–152. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).